| Literature DB >> 36017197 |
Mohammad Amiri1, Daniel Elieh Ali Komi2, Asad Vaisi-Raygani3, Amir Kiani2, Mahmoudreza Moradi2, Mahdieh Aliyari1, Zohreh Rahimi4, Ehsan Mohammadi-Noori5, Homayoon Bashiri6.
Abstract
Prostate cancer (PCa) pathology has been linked to vitamin D, vitamin D receptors (VDRs), and vitamin D binding proteins (VDBPs). We sought to investigate the association between VDR rs2228570 and rs1544410 as well as VDBP rs7041 polymorphisms and serum 25-hydroxyvitamin D (25(OH)-vitamin D) levels in PCa patients. Blood samples were collected from 111 PCa patients and 150 age-matched healthy volunteers. The VDR rs2228570 T/C, rs1544410 G/A, and VDBP rs7041 T/G genotypes were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 25(OH)-vitamin D and PSA (Total and Free) serum levels were measured. The frequencies of VDBP genotypes T/G vs. T/T (56.5% vs. 44.5%, p = 0.01) according to the dominant model T/G + G/G vs. T/T (84.3% vs. 71.5%, p = 0.01) were significantly higher in PCa patients when compared to control group and considerably increased the risk of disease by 2.29, 1.44, and 2.13 folds respectively. Interestingly, the results demonstrated that PCa patients with the dominant model (T/G + G/G vs. T/T) of VDBP had significantly lower serum levels of vitamin D and higher serum levels of total and free PSA in comparison to the controls. Furthermore, when compared to controls, PCa patients with the dominant model T allele (T/G + G/G vs. TT) of VDBP had significantly higher vitamin D, total PSA, and free PSA concentrations. Serum levels of 25(OH)-vitamin D and rs7041 T/G polymorphism of the VDBP gene could be potential risk factors for PCa.Entities:
Keywords: 25(OH)-vitamin D; polymorphism; prostate cancer; vitamin D binding protein; vitamin D receptor
Mesh:
Substances:
Year: 2022 PMID: 36017197 PMCID: PMC9395586 DOI: 10.3389/pore.2022.1610246
Source DB: PubMed Journal: Pathol Oncol Res ISSN: 1219-4956 Impact factor: 2.874
FIGURE 1(A) Agarose gel electrophoresis (1.5%) pattern of VDR rs2228570 T/C digested PCR products with FOK I enzyme. From left to right lanes 2, 3, 5, and 7 indicate HOM: homozygous mutant (CC: 265 bp), lanes 1, 4, and 8 demonstrate HET; heterozygous mutant (TC: 265, 196, 69 bp); lanes 6 indicates WT; homozygous wild-type (TT: 196 bp and 69 bp). (DNA ladder = 50 bp), (B) Agarose gel electrophoresis (1.5%) pattern of VDR rs1544410 G/A digested PCR products with BsmI enzyme. From left to right lanes 1, 2, 3, and 4 indicate HOM, homozygous mutant (AA: 822 bp); lanes 5, 6, and 8 demonstrate HET: heterozygous mutant (AG: 822, 645, 177 bp), lanes 4 indicates WT: homozygous wild-type (GG: 645bp and 177 bp). (DNA ladder = 100 bp) (C) Agarose gel electrophoresis (1.5%) pattern of VDBP rs7041 T/G digested PCR products with HaeIII enzyme. From left to right lanes with two 185 and 298 bp bands indicate GG phenotype (lanes 2, 3, 8, 9, 11, 12, and 15), lanes with three bands (185, 298, and 483 bp) indicate heterozygote TG phenotype (lanes 1, 4, 5, 6, 7, 10, 13, and 14), and lane 16 with a single 483 bp band, indicates wild type TT phenotype.
The demographic characteristic and distribution of risk factors in prostatic cancer patients and control subjects in a population from the west of Iran.
| Parameters | PCa (N = 111) | Control (N = 150) |
|
|---|---|---|---|
| Age | 67.7 ± 11.2 | 66.2 ± 11.3 | 0.613 |
| Diabetic | No 84 (75.7%) | No 127 (84.7%) | 0.068 |
| Yes 27 (24.3%) | Yes 23 (15.3%) | ||
| Smoker | No 53 (47.7%) | No 109 (72.7%) | <0.001 |
| Yes 58 (52.3%) | Yes 41 (27.3%) | ||
| BMI (kg/m2) | 24.5 (14.7–35.8) | 25.6 (14.9–43.3) | 0.015 |
| 25(OH)-vitamin D (ng/ml) | 16.2 (0.3–54.1) | 23.2 (0.3–89.8) | <0.001 |
| Total PSA (ng/L) | 76.8 (0.4–572) | 0.9 (0.09–3.1) | <0.001 |
| Free PSA (ng/L) | 14.5 (0.1–109) | 0.4 (0.1–1.9) | <0.001 |
| Free PSA/Total PSA | 0.21 (0.01–2.5) | 0.48 (0.01–3.5) | <0.001 |
Compared serum total PSA, free PSA, and 25(OH)-vitamin D levels and the ratio of Free PSA/Total PSA, BMI, and age between patients and controls were used two-tailed Student’s t-test.
Odds ratio (95% confidential interval) and distribution of VDR (rs2228570) T/C and (rs1544410) G/A genotypes and alleles in patients with PCa and control subjects.
| SNP | Genotype | PCa (N = 111) | Control (N = 150) |
|---|---|---|---|
| rs2228570 | T/T | 6 (4.1%) | 6 (5.5%) |
| T/C | 41 (37.6%) | 48 (32.7%) | |
| ( | |||
| 0.85 (0.25–2.85, | |||
| C/C | 62 (56.9%) ( | 93 (63.3%) | |
| 0.82 (0.45–1.47, | |||
| ( | |||
| Dominant model | |||
| T/T | 6 (5.5%) | 6 (4.1%) | |
| T/C + C/C | 103 (94.5%) | 141 (95.9%) | |
| ( | |||
| 0.73 (0.23–2.33, | |||
| rs1544410 | G/G | 33 (30%) | 45 (30.6%) |
| G/A | 61 (55.5%) | 78 (53.1%) | |
| ( | |||
| 1.07 (0.61–1.87, | |||
| A/A | 16 (14.5%) | 24 (16.3%) | |
| ( | |||
| 0.95 (0.64–1.4, | |||
| (χ2 = 0.203, df = 2, | |||
| Dominant model | |||
| G/G | 33 (30%) | 45 (30.6%) | |
| G/A + A/A | 77 (70%) | 102 (69.4%) | |
| ( | |||
| 1.03 (0.61–1.76, | |||
Odds ratio (95% confidential interval) and distribution of VDBP (rs7041) T/G genotypes and alleles in patients with PCa and control subjects.
| SNP | Genotype | PCa (N = 111) | Control (N = 150) |
|---|---|---|---|
| rs7041 | T/T | 17 (15.7%) | 39 (28.5%) |
| T/G | 61 (56.5%) | 61 (44.5%) | |
| ( | 37 (27%) | ||
| 2.29 (1.17–4.49, | |||
| G/G | 30 (27.8%) (χ2 = 2.68, df = 1, | ||
| 1.36 (0.93–1.98, | |||
| ( | |||
| Dominant model | |||
| T/T | 17 (15.7%) | 39 (28.5%) | |
| T/G + G/G | 91 (84.3%) | 98 (71.5%) | |
| ( | |||
| Alleles | |||
| T | 95 (44%) | 139 (50.7%) | |
| G | 121 (56%) | 135 (49.3%) | |
| ( | |||
| 1.31 (0.84–2.34, |
The concentration of vitamin D, total PSA, free PSA, and free PSA/total PSA with the dominant model of VDBP genotypes (T/G + G/G, T/T) comprised between PCa patients and control subjects.
| Parameter | PCa (N = 111) | Control (N = 150) |
|
|---|---|---|---|
|
| N = 17 | N = 39 | |
| 25(OH)-vitamin D (ng/ml) | 16.69 | 19.65 | 0.369 |
| Total PSA (ng/L) | 81.46 | 0.88 | <0.001 |
| Free PSA (ng/L) | 12.69 | 0.48 | <0.001 |
| Free PSA/Total PSA | 0.19 | 0.64 | 0.008 |
|
| N = 91 | N = 98 | |
| 25(OH)-vitamin D (ng/ml) | 16.52 | 24.71 | <0.001 |
| Total PSA (ng/L) | 73.58 | 0.89 | <0.001 |
| Free PSA (ng/L) | 13.86 | 0.37 | <0.001 |
| Free PSA/Total PSA | 0.22 | 0.43 | <0.001 |
Association between clinical parameters and PCa severity.
| Parameter | Gleason score GS ≥ 7 | Gleason score GS < 7 |
|
|---|---|---|---|
| 25(OH)-vitamin D (ng/ml) | 15.3 | 17.6 | 0.304 |
| Total PSA (ng/L) | 100.6 | 44.3 | <0.001 |
| Free PSA (ng/L) | 20.8 | 6.8 | <0.001 |
| Free PSA/Total PSA | 0.19 | 0.23 | 0.51 |